Premium
Immunohistochemical comparison of spindle cell lesions: Schwannoma versus fibroblastic meningioma
Author(s) -
Rishi Kirtee,
Coffey Donna,
Javed Rehana,
Powell Suzanne Z,
Takei Hidehiro
Publication year - 2007
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.21.5.a389-a
Subject(s) - schwannoma , immunohistochemistry , pathology , meningioma , s100 protein , medicine
Distinguishing fibroblastic meningioma from schwannoma can be challenging for the pathologist especially in the cerebellopontine angle and often warrants additional studies to elucidate a diagnosis. We determined the pattern of immunohistochemical expression of CD56, CD57, S100 protein and EMA in 30 cases of schwannoma and 39 cases of fibroblastic meningioma. The mean age of the patients in both the groups was similar (56 years). Sections were graded semi‐quantitatively for intensity (0–3) and extent of staining (0–4) with total score ranging from 0–7. Immunoreactivity of CD56, CD57, S100 protein and EMA was seen in 97, 47, 100 and 3% of cases of schwannoma respectively. Immunoreactivity of CD56, CD57, S100 protein and EMA was seen in 21, 0, 18 and 87% of cases of fibroblastic meningioma respectively. There was statistically significant difference for CD56, CD57, S100 protein and EMA expression between schwannoma and fibroblastic meningioma (p < .0001; Mann‐Whitney Analysis). There was also statistically significant positive correlation in expression of CD56 and S100 protein in the schwannoma group (r= .628, p= .0007; Spearman correlation). We conclude that an immunohistochemical panel of CD56, CD57, S100 protein and EMA can help in the diagnoses of schwannoma versus fibroblastic meningioma.